Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
The hexenoyl cap is there to resist DPP-IV. The biology is still a GHRH pulse at the pituitary, then GH, then hepatic IGF-1.
It is not a growth-hormone injection and not an androgen.
It is a GHRH analog with a real labeled setting: reduction of visceral fat in HIV-associated lipodystrophy. The pathway is pituitary GH release and then IGF-1.
Forum use outside that setting does not change the receptor. It also does not create an androgen pathway.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
Visceral-fat talk beyond the label · unverified
The labeled HIV-lipodystrophy use leaks into general fat-loss threads. IGF-1 worries and glucose worries show up beside androgen talk. The pathway on file is still GHRH, not an androgen.
Theme summarized from public discussion. Not a quoted post, not a trial, and not a dose.